Skip to content

Advertisement

Archived Comments for: The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women

Back to article

  1. Comment

    Robert Borden Hopkins, PATH Research Institute

    29 February 2012

    After the work [1] was published we realized a minor error with regard to contents.

    In Table 1, there were two studies by the author Cummings. The first study was published in 1998 with the drug alendronate [2]. The second study published by Cummings in 2009 involved denosumab [3]. During the editorial process, we submitted the description of study and baseline characteristics to be identical for 1998 study and the 2009 study, which they are not. The 2009 study published by Cummings involved denosumab versus placebo, was a 3 year study, that was international in 182 sites, with baseline age of 72.3(5.2) (mean(SD)), the years since menopause as an inclusion criteria and baseline years since menopause were not reported, baseline BMD was also not reported, and the percent of prior vertebral fracture was 23.6%. The authors regret any confusion by our editorial error. The statistical analysis was not affected.

    References
    1. Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, Thabane L. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women BMC Musculoskelet Disord. 2011 Sep 26;12(1):209.

    2. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077-82.

    3. Cummings SR, San MJ, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756-65.

    Competing interests

    None declared

Advertisement